These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
320 related articles for article (PubMed ID: 19018725)
1. New trends in pharmacogenomic strategies against resistance development in microbial infections. Ohlsen K; Dandekar G; Schwarz R; Dandekar T Pharmacogenomics; 2008 Nov; 9(11):1711-23. PubMed ID: 19018725 [TBL] [Abstract][Full Text] [Related]
2. Importance of antibiotic resistance and resistance mechanisms. Foreword. Bonomo RA; Rossolini GM Expert Rev Anti Infect Ther; 2008 Oct; 6(5):549-50. PubMed ID: 18847392 [No Abstract] [Full Text] [Related]
3. Antimicrobial resistance in Europe and its potential impact on empirical therapy. Rossolini GM; Mantengoli E Clin Microbiol Infect; 2008 Dec; 14 Suppl 6():2-8. PubMed ID: 19040461 [TBL] [Abstract][Full Text] [Related]
4. Pharmacogenomic strategies against microbial resistance: from bright to bleak to innovative. Dandekar T; Dandekar G Pharmacogenomics; 2010 Sep; 11(9):1193-6. PubMed ID: 20860457 [TBL] [Abstract][Full Text] [Related]
5. Mechanisms of β-lactam antimicrobial resistance and epidemiology of major community- and healthcare-associated multidrug-resistant bacteria. Tang SS; Apisarnthanarak A; Hsu LY Adv Drug Deliv Rev; 2014 Nov; 78():3-13. PubMed ID: 25134490 [TBL] [Abstract][Full Text] [Related]
6. Resistance in antimicrobial photodynamic inactivation of bacteria. Maisch T Photochem Photobiol Sci; 2015 Aug; 14(8):1518-26. PubMed ID: 26098395 [TBL] [Abstract][Full Text] [Related]
7. The role of integrons in antibiotic resistance gene capture. Rowe-Magnus DA; Mazel D Int J Med Microbiol; 2002 Jul; 292(2):115-25. PubMed ID: 12195734 [TBL] [Abstract][Full Text] [Related]
8. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Sader HS; Jones RN; Dowzicky MJ; Fritsche TR Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565 [TBL] [Abstract][Full Text] [Related]
9. Shifting trends in bacterial keratitis in Toronto: an 11-year review. Lichtinger A; Yeung SN; Kim P; Amiran MD; Iovieno A; Elbaz U; Ku JY; Wolff R; Rootman DS; Slomovic AR Ophthalmology; 2012 Sep; 119(9):1785-90. PubMed ID: 22627118 [TBL] [Abstract][Full Text] [Related]
10. Risk factors and etiology of neonatal sepsis in Tikur Anbessa University Hospital, Ethiopia. Shitaye D; Asrat D; Woldeamanuel Y; Worku B Ethiop Med J; 2010 Jan; 48(1):11-21. PubMed ID: 20607993 [TBL] [Abstract][Full Text] [Related]
11. Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Sutcliffe JA; O'Brien W; Fyfe C; Grossman TH Antimicrob Agents Chemother; 2013 Nov; 57(11):5548-58. PubMed ID: 23979750 [TBL] [Abstract][Full Text] [Related]
12. Tigecycline: a novel glycylcycline antibiotic. Zhanel GG; Karlowsky JA; Rubinstein E; Hoban DJ Expert Rev Anti Infect Ther; 2006 Feb; 4(1):9-25. PubMed ID: 16441206 [TBL] [Abstract][Full Text] [Related]
13. What is in the pipeline for Gram-negative pathogens? Talbot GH Expert Rev Anti Infect Ther; 2008 Feb; 6(1):39-49. PubMed ID: 18251663 [TBL] [Abstract][Full Text] [Related]
14. Anaerobes: antibiotic resistance, clinical significance, and the role of susceptibility testing. Hecht DW Anaerobe; 2006 Jun; 12(3):115-21. PubMed ID: 16765857 [No Abstract] [Full Text] [Related]
15. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). Streit JM; Jones RN; Sader HS; Fritsche TR Int J Antimicrob Agents; 2004 Aug; 24(2):111-8. PubMed ID: 15288308 [TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo antibacterial activities of SM-216601, a new broad-spectrum parenteral carbapenem. Ueda Y; Kanazawa K; Eguchi K; Takemoto K; Eriguchi Y; Sunagawa M Antimicrob Agents Chemother; 2005 Oct; 49(10):4185-96. PubMed ID: 16189097 [TBL] [Abstract][Full Text] [Related]
17. Reversal of resistance in microorganisms by help of non-antibiotics. Kristiansen JE; Hendricks O; Delvin T; Butterworth TS; Aagaard L; Christensen JB; Flores VC; Keyzer H J Antimicrob Chemother; 2007 Jun; 59(6):1271-9. PubMed ID: 17403708 [TBL] [Abstract][Full Text] [Related]
18. In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, gram-negative and gram-positive clinical isolates from Greek hospitals. Souli M; Kontopidou FV; Koratzanis E; Antoniadou A; Giannitsioti E; Evangelopoulou P; Kannavaki S; Giamarellou H Antimicrob Agents Chemother; 2006 Sep; 50(9):3166-9. PubMed ID: 16940120 [TBL] [Abstract][Full Text] [Related]
19. Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004). Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN Diagn Microbiol Infect Dis; 2005 Jul; 52(3):195-201. PubMed ID: 16105564 [TBL] [Abstract][Full Text] [Related]
20. [Antibiotic therapy by suppurative diseases of the abdominal cavity and soft tissues]. Sazhin VP; Bodrova NG; Klimov DE; Iurishchev VA; Avdovenko AL; Sazhin IV Khirurgiia (Mosk); 2010; (6):4-9. PubMed ID: 20559216 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]